Literature DB >> 10169347

Why activity-based costing works.

S G Gabram1, R A Mendola, J Rozenfeld, R L Gamelli.   

Abstract

With advancing technology and the quest for delineating the true cost of a procedure or diagnostic test, cost accounting techniques are being re-explored in the health care setting. Activity-based costing (ABC), adopted from other businesses, is one such example that has applications in the health industry. The purpose of this paper is to enhance the understanding of health care costs among physician providers, emphasizing a new approach--activity-based costing.

Mesh:

Year:  1997        PMID: 10169347

Source DB:  PubMed          Journal:  Physician Exec        ISSN: 0898-2759


  6 in total

1.  Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa.

Authors:  Kenneth R Meehan; N Simon Tchekmedyian; Robert E Smith; Joel Kallich
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

2.  Is a methodology available that accurately measures the cost of an FDG-PET study?

Authors:  Bruno Krug; Anne Sophie Pirson; Ralph Crott; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-08       Impact factor: 9.236

3.  Activity-based costing evaluation of [18F]-fludeoxyglucose production.

Authors:  Bruno Krug; Annie Van Zanten; Anne-Sophie Pirson; Ralph Crott; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-21       Impact factor: 9.236

4.  Cost comparison of open approach, transoral laser microsurgery and transoral robotic surgery for partial and total laryngectomies.

Authors:  Manon Dombrée; Ralph Crott; Georges Lawson; Pascal Janne; Annick Castiaux; Bruno Krug
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-07       Impact factor: 2.503

5.  Patient and caregiver time burden associated with anaemia treatment in different patient populations.

Authors:  Arthur C Houts; Geoffrey A Loh; Barry V Fortner; Joel D Kallich
Journal:  Support Care Cancer       Date:  2006-05-03       Impact factor: 3.603

6.  Importance of nondrug costs of intravenous antibiotic therapy.

Authors:  Arthur R H van Zanten; Peter M Engelfriet; Karin van Dillen; Miriam van Veen; Mark J C Nuijten; Kees H Polderman
Journal:  Crit Care       Date:  2003-10-14       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.